What is Neuropace, Inc.'s R&D?

Neuropace, Inc. (NPCE) reported R&D of $7.19M in Q1 2026.

How has Neuropace, Inc.'s R&D changed year-over-year?

Neuropace, Inc.'s R&D decreased by 3.4% year-over-year, from $7.44M to $7.19M.

What is the long-term trend for Neuropace, Inc.'s R&D?

Over 4 years (2021 to 2025), Neuropace, Inc.'s R&D has grown at a 11.2% compound annual growth rate (CAGR), from $18.21M to $27.89M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Neuropace, Inc. NPCE R&D

R&D at other companies

MedtronicMDT

$671M-1.9%

LivaNovaLIVN

$58.7M+55.0%

ClearPoint NeuroCLPT

$4.52M+33.8%

Inspire Medical SystemsINSP

$25.83M-7.1%

Orthofix Medical Inc.OFIX

$15.32M-22.5%

ARS Pharmaceuticals, Inc.SPRY

$4.34M+46.9%

Other financials

Income statement

See full

Revenue$22.1M-2.0%

Gross profit$18.0M+4.1%

Operating income-$5.6M-8.2%

Net income-$6.7M-1.5%

EPS (diluted)-$0.20+4.8%

Balance sheet

See full

Cash & equivalents$15.6M-42.4%

Total debt$70.5M-3.7%

Total equity$14.5M-40.4%

Total assets$98.9M-10.3%

Cash flow

See full

Operating cash flow-$5.9M+21.1%

CapEx$117.0K+216%

Free cash flow-$6.0M+20.0%

Valuation

See full

Market cap$557.77M+63.4%

Enterprise value$612.6M+58.1%

P/S5.6×+1.6×

Profitability

See full

Gross margin78.3%+3.5pp

Operating margin-16.8%-3.5pp

Net margin-21.7%-4.5pp

FCF margin-10.3%-3.5pp

Returns & leverage

See full

Return on equity-111.4%-13.1pp

Debt / equity4.9×+1.9×

Current ratio5.4×-1.2×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Neuropace, Inc.'s R&D?: Neuropace, Inc. (NPCE) reported R&D of $7.19M in Q1 2026.
How has Neuropace, Inc.'s R&D changed year-over-year?: Neuropace, Inc.'s R&D decreased by 3.4% year-over-year, from $7.44M to $7.19M.
What is the long-term trend for Neuropace, Inc.'s R&D?: Over 4 years (2021 to 2025), Neuropace, Inc.'s R&D has grown at a 11.2% compound annual growth rate (CAGR), from $18.21M to $27.89M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.